Ahmed M Abu El-Asrar1, Ghulam Mohammad2, Mohd Imtiaz Nawaz2, Mohammed Abdelsaid3, Mohammad Mairaj Siddiquei2, Kaiser Alam2, Kathleen Van den Eynde4, Gert De Hertogh4, Ghislain Opdenakker5, Mohamed Al-Shabrawey3, Jo Van Damme6, Sofie Struyf6. 1. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia Dr Nasser Al-Rashid Research Chair in Ophthalmology, King Saud University, Riyadh, Saudi Arabia. 2. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 3. Department of Oral Biology, Cellular Biology and Anatomy, Culver Vision Discovery Institute and Department of Ophthalmology, Georgia Regents University, Augusta, Georgia, United States. 4. Laboratory of Histochemistry and Cytochemistry, University of Leuven, KU Leuven, Leuven, Belgium. 5. Laboratory of Immunobiology, Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, KU Leuven, Leuven, Belgium. 6. Laboratory of Molecular Immunology, Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, KU Leuven, Leuven, Belgium.
Abstract
PURPOSE: To investigate the expression of platelet factor-4 variant (PF-4var/CXCL4L1) in epiretinal membranes from patients with proliferative diabetic retinopathy (PDR) and the role of PF-4var/CXCL4L1 in the regulation of blood-retinal barrier (BRB) breakdown in diabetic rat retinas and human retinal microvascular endothelial cells (HRMEC). METHODS: Rats were treated intravitreally with PF-4var/CXCL4L1 or the anti-vascular endothelial growth factor (VEGF) agent bevacizumab on the first day after diabetes induction. Blood-retinal barrier breakdown was assessed in vivo with fluorescein isothiocyanate (FITC)-conjugated dextran and in vitro in HRMEC by transendothelial electrical resistance and FITC-conjugated dextran cell permeability assay. Occludin, vascular endothelial (VE)-cadherin, hypoxia-inducible factor (HIF)-1α, VEGF, tumor necrosis factor (TNF)-α, receptor for advanced glycation end products (RAGE), caspase-3 levels, and generation of reactive oxygen species (ROS) were assessed by Western blot, enzyme-linked immunosorbent assays, or spectrophotometry. RESULTS: In epiretinal membranes, vascular endothelial cells and stromal cells expressed PF-4var/CXCL4L1. In vitro, HRMEC produced PF-4var/CXCL4L1 after stimulation with a combination of interleukin (IL)-1β and TNF-α, and PF-4var/CXCL4L1 inhibited VEGF-mediated hyperpermeability in HRMEC. In rats, PF-4var/CXCL4L1 was as potent as bevacizumab in attenuating diabetes-induced BRB breakdown. This effect was associated with upregulation of occludin and VE-cadherin and downregulation of HIF-1α, VEGF, TNF-α, RAGE, and caspase-3, whereas ROS generation was not altered. CONCLUSIONS: Our findings suggest that increasing the intraocular PF-4var/CXCL4L1 levels early after the onset of diabetes protects against diabetes-induced BRB breakdown. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To investigate the expression of platelet factor-4 variant (PF-4var/CXCL4L1) in epiretinal membranes from patients with proliferative diabetic retinopathy (PDR) and the role of PF-4var/CXCL4L1 in the regulation of blood-retinal barrier (BRB) breakdown in diabeticrat retinas and human retinal microvascular endothelial cells (HRMEC). METHODS:Rats were treated intravitreally with PF-4var/CXCL4L1 or the anti-vascular endothelial growth factor (VEGF) agent bevacizumab on the first day after diabetes induction. Blood-retinal barrier breakdown was assessed in vivo with fluorescein isothiocyanate (FITC)-conjugated dextran and in vitro in HRMEC by transendothelial electrical resistance and FITC-conjugated dextran cell permeability assay. Occludin, vascular endothelial (VE)-cadherin, hypoxia-inducible factor (HIF)-1α, VEGF, tumor necrosis factor (TNF)-α, receptor for advanced glycation end products (RAGE), caspase-3 levels, and generation of reactive oxygen species (ROS) were assessed by Western blot, enzyme-linked immunosorbent assays, or spectrophotometry. RESULTS: In epiretinal membranes, vascular endothelial cells and stromal cells expressed PF-4var/CXCL4L1. In vitro, HRMEC produced PF-4var/CXCL4L1 after stimulation with a combination of interleukin (IL)-1β and TNF-α, and PF-4var/CXCL4L1 inhibited VEGF-mediated hyperpermeability in HRMEC. In rats, PF-4var/CXCL4L1 was as potent as bevacizumab in attenuating diabetes-induced BRB breakdown. This effect was associated with upregulation of occludin and VE-cadherin and downregulation of HIF-1α, VEGF, TNF-α, RAGE, and caspase-3, whereas ROS generation was not altered. CONCLUSIONS: Our findings suggest that increasing the intraocular PF-4var/CXCL4L1 levels early after the onset of diabetes protects against diabetes-induced BRB breakdown. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Jo Vandercappellen; Sandra Liekens; Annelies Bronckaers; Samuel Noppen; Isabelle Ronsse; Chris Dillen; Mirella Belleri; Stefania Mitola; Paul Proost; Marco Presta; Sofie Struyf; Jo Van Damme Journal: Mol Cancer Res Date: 2010-03-09 Impact factor: 5.852
Authors: Sofie Struyf; Laura Salogni; Marie D Burdick; Jo Vandercappellen; Mieke Gouwy; Sam Noppen; Paul Proost; Ghislain Opdenakker; Marc Parmentier; Craig Gerard; Silvano Sozzani; Robert M Strieter; Jo Van Damme Journal: Blood Date: 2010-10-27 Impact factor: 22.113
Authors: Dawid M Kaczor; Rafael Kramann; Tilman M Hackeng; Leon J Schurgers; Rory R Koenen Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 5.923